Central auditory dysfunction is a precursor to AD. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Increased SBP and low milk intake in midlife were associated with VaD detected 25 to 30 years later. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
We found that 451 (92.8%) of the patients were testable, 239 (49.2%) of the patients were women, and the mean age was 71.2 years. 5 key findings →
Participants: 486 Evidence: moderate
Full summary, score breakdown and related studies → Original source
52/100
TBI is an independent significant risk factor of developing dementia even in the mild type. 3 key findings →
Participants: 28,551 Evidence: low
Full summary, score breakdown and related studies → Original source
We examined 204 decedents of the autopsy component of the Honolulu-Asia Aging Study, a longitudinal cohort study, who had been clinically assessed for dementia. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the Cardiovascular Health Cognition Study, consumption of fatty fish was associated with a reduced risk of dementia and Alzheimer disease for those without the APOE epsilon4 allele. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Additional (not mutually exclusive) explanations for findings are discussed. 1 key finding →
Participants: 255 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among type 2 diabetic patients followed for 10 years, African Americans and Native Americans had a 40-60% greater risk of dementia compared with Asians, and risk was intermediate for non-Hispanic whites and Latinos. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Rare variants should only be investigated in users with a family history of early-onset dementia in a first degree relative. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Disturbed sleep cycles are the principal cause of institutionalization in dementia, and therefore represent a major clinical problem. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that includes obesity, diabetes, and dyslipidemia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Obstructive sleep apnea (OSA) is highly prevalent but very frequently undiagnosed. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
51/100
Vascular risk factors for Alzheimer disease (AD) and vascular dementia (VaD) have been evaluated; however, few studies have compared risks by dementia subtypes and sex. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The current study examined the interactive effect of type 2 diabetes and Alzheimer disease (AD) risk factors on the rate of functional decline in cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative. 4 key findings →
Design: longitudinal study Participants: 69 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Data from 2,133 participants with autopsy-confirmed AD (i.e., at least Braak neurofibrillary tangle stages III to VI and CERAD neuritic plaque score moderate to frequent) were obtained from the National Alzheimer's Coordinating Center (NACC). 4 key findings →
Participants: 194 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Serum lipid traits are associated with cardiovascular disease, but uncertainty remains regarding their associations with dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The association of testosterone concentrations with dementia risk remains uncertain. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Being overweight or obese, as measured with body-mass index or central adiposity (waist circumference), and the trajectory of body-mass index over the life course have been associated with brain atrophy, white matter changes, disturbances of blood-brain barrier integrity, and risk of all-cause late-onset dementia and Alzheimer's disease. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.041). Socioeconomic status and residential area are associated with long-term survival in patients with EOD. 2 key findings →
Design: cohort study Participants: 3,825 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study population consisted of 16,981 individuals (mean age: 62.4, 51.6% female, 68.7% non-Hispanic White, 15.5% in rural areas). 5 key findings →
Design: cross-sectional Participants: 16,981 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fine particulate matter, known as PM 2.5, is recognized as a risk factor for dementia. 1 key finding →
Participants: 217,336 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 934,792 individuals, 81,731 developed dementia over a mean follow-up of 11·6 years. 1 key finding →
Participants: 934,792 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There was a significant difference in dementia incidence in the HSV-infected group versus the control. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified 132,968 individuals, of whom 12,088 with severe Zoster, 60,440 matched controls among the general population, and 60,440 matched controls among the hospitalised population. 5 key findings →
Participants: 132,968 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up of 8.2 years, YOD incidence increased progressively with higher WC. 5 key findings →
Participants: 964,536 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
9 of the 1,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument
- Anxiety is not associated with the risk of dementia or cognitive decline: the Rotterdam Study
- Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins
- Gait characteristics and factors associated with fall risk in patients with dementia with Lewy bodies
- Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy
- The role of sleep in dementia prevention: building the case for causality
- Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial
- Sleep and physical activity trade-offs and dementia risk: a prospective cohort study in UK Biobank participants
- Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →